ADX10059 is a potent, selective, negative allosteric modulator of metabotropic glutamate receptor 5 (mGluR5 NAM). Various pre-clinical pharmacology experiments have shown that glutamate is largely responsible for signal transmission in the neural circuit involved in migraine, and mGluR5 receptors are found at strategic points along the pathway.
The Phase IIA clinical trial met its primary endpoint, wherein ADX10059 demonstrated a statistically significant higher number of patients pain-free 2 hours after dosing compared to placebo.
According to Dr Vincent Mutel, CEO of Addex:
"These results are the first demonstration of the involvement of mGluR5 in the migraine process. We believe that ADX10059 could play a significant role in the long term management of this disease, and have given the green light to initiate a Phase IIb trial."Find more details from the full report.
.jpg)
Comment Preview